Aaron Cowen Suvretta Capital Management
Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Legend Biotech
LEGN
|
+$145M |
| 2 |
Immatics
IMTX
|
+$43.5M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$38.6M |
| 4 |
Coca-Cola
KO
|
+$35.8M |
| 5 |
Caesars Entertainment
CZR
|
+$30.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$78.3M |
| 2 |
ACLX
Arcellx
ACLX
|
+$57.6M |
| 3 |
Royalty Pharma
RPRX
|
+$52.8M |
| 4 |
AT&T
T
|
+$50.3M |
| 5 |
UnitedHealth
UNH
|
+$40.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.9% |
| 2 | Consumer Discretionary | 8.93% |
| 3 | Technology | 8.81% |
| 4 | Financials | 5.59% |
| 5 | Communication Services | 4.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
CVS Health
CVS
$119B
| – | – |
-17,170
| Closed | -$1.08M |
|
102
iShares China Large-Cap ETF
FXI
$4.28B
| – | – |
-242,500
| Closed | -$7.71M |
|
103
Illumina
ILMN
$33.1B
| – | – |
-8,730
| Closed | -$1.14M |
|
104
CALL
Intel
INTC
$476B
| – | – |
-1,000,000
| Closed | -$23.5M |
|
105
Keurig Dr Pepper
KDP
$43.6B
| – | – |
-703,095
| Closed | -$26.4M |
|
106
Kenvue
KVUE
$36.6B
| – | – |
-171,596
| Closed | -$3.97M |
|
107
KraneShares CSI China Internet ETF
KWEB
$5.28B
| – | – |
-230,000
| Closed | -$7.82M |
|
108
Las Vegas Sands
LVS
$30.5B
| – | – |
-484,110
| Closed | -$24.4M |
|
109
Pinterest
PINS
$13.3B
| – | – |
-615,911
| Closed | -$19.9M |
|
|
110
Royalty Pharma
RPRX
$27.3B
| – | – |
-1,866,361
| Closed | -$52.8M |
|
|
111
AT&T
T
$173B
| – | – |
-2,285,336
| Closed | -$50.3M |
|
112
Bio-Techne
TECH
$11.3B
| – | – |
-2,600
| Closed | -$208K |
|
113
Teva Pharmaceuticals
TEVA
$43.5B
| – | – |
-268,100
| Closed | -$4.83M |
|
114
Wynn Resorts
WYNN
$10.3B
| – | – |
-133,000
| Closed | -$12.8M |
|
|
MRNS
115
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| – | – |
-5,073,913
| Closed | -$8.93M |
|
Similar funds
Aaron Cowen's Q4 2024 Portfolio in Review
As of Q4 2024, Aaron Cowen held 115 positions worth $2.93B, down 6.1% from $3.13B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Aaron Cowen's Q4 2024 filing shows 17 new, 19 increased, 24 reduced and 19 closed positions. Its largest new stake was Legend Biotech: 3,496,234 shares worth $114M. The largest sale was Apple, an estimated $78.3M.
By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 53% a quarter earlier, followed by Consumer Discretionary and Technology.
- Aaron Cowen's largest Q4 2024 buy was Legend Biotech: 3,496,234 shares worth $114M.
- Aaron Cowen added most to Coca-Cola in Q4 2024, an estimated $35.8M increase.
- Aaron Cowen's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $40.7M.
- Aaron Cowen fully exited Apple in Q4 2024, selling an estimated $78.3M.
- Aaron Cowen's ten largest holdings make up 44% of its $2.93B portfolio in Q4 2024.
- Aaron Cowen opened 17 new positions and closed 19 in Q4 2024.
- Aaron Cowen's portfolio value fell 6.1% quarter-over-quarter to $2.93B.
Based on Suvretta Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.